Belinostat

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 362 publications

Deciphering the Leading-Edge Spatiotemporal Microenvironment of Hepatocellular Carcinoma for Targeted Drug Discovery Using SpaPred.

Deciphering the Leading-Edge Spatiotemporal Microenvironment of Hepatocellular Carcinoma for Targeted Drug Discovery Using SpaPred.

Journal: International journal of molecular sciences

Published: July 04, 2026

Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology.

Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology.

Journal: Journal of clinical medicine

Published: June 24, 2026

From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs.

From design to clinic: Medicinal chemistry and pharmacology of approved epigenetic drugs.

Journal: European journal of medicinal chemistry

Published: May 19, 2026

Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.

Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.

Journal: Journal of clinical medicine

Published: May 07, 2026

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 21, 2026

Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.

Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 31, 2026

A Six-year Response to Belinostat in a Highly Probable Case of Relapsed/Refractory MF/SS Initially Classified as PTCL-NOS: A Case Report.

A Six-year Response to Belinostat in a Highly Probable Case of Relapsed/Refractory MF/SS Initially Classified as PTCL-NOS: A Case Report.

Journal: OncoTargets and therapy

Published: March 13, 2026

Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.

Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy.

Journal: Theranostics

Published: February 24, 2026

Variant-dependent pharmacological rescue of phenylalanine hydroxylase supports a precision therapeutic strategy for phenylketonuria.

Variant-dependent pharmacological rescue of phenylalanine hydroxylase supports a precision therapeutic strategy for phenylketonuria.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 12, 2026

Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma.

Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma.

Journal: Stem cells international

Published: February 05, 2026

Screening and evaluation of potential histone deacetylase inhibitors against Babesia infections.

Screening and evaluation of potential histone deacetylase inhibitors against Babesia infections.

Journal: International journal for parasitology. Drugs and drug resistance

Published: January 07, 2026

Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework.

Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework.

Journal: Biomedical chromatography : BMC

Published: November 21, 2025

Showing 1-12 of 362

Last Updated: 09/26/2026